Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Geriatrics and Gerontology
Reference13 articles.
1. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68(6):685–9.
2. US Food and Drug Administration. FDA drug safety communication: ongoing safety review of Parkinson’s drug Mirapex (pramipexole) and possible risk of heart failure. http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm#data . Accessed 16 Jan 2013.
3. Renoux C, Dell’Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21(1):34–41.
4. Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res. 2012;65(3):358–64.
5. Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan’s national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal. 2007;15(2):99–108.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献